ERBB2 and cancer: This highlights the potential for combining immunotherapy with myeloid-targeting strategies.158 Targeted therapies showed promising outcomes in advanced unresectable or metastatic gastric or gastro-esophageal junction adenocarcinoma, such as trastuzumab for Human Epidermal growth factor Receptor 2 (HER2)-positive tumors and zolbetuximab, a monoclonal antibody targeting claudin-18 isoform 2 (Claudin 18.2)-positive cancers, alongside IC inhibitors like nivolumab.159,160